US2016067238A1PendingUtilityA1

Pharmaceutical composition and uses thereof

40
Assignee: WU PHILIPPriority: May 6, 2013Filed: May 5, 2014Published: Mar 10, 2016
Est. expiryMay 6, 2033(~6.8 yrs left)· nominal 20-yr term from priority
Inventors:Pei-Chang WuChia-Ling TsaiChueh-Tan Chen
A61P 27/10A61P 43/00A61P 9/00A61P 27/02A61P 29/00A61P 19/00A61K 31/196A61K 31/405A61K 31/165A61K 31/407A61K 45/06A61K 31/46A61K 31/192A61K 2300/00A61K 2121/00A61P 19/08
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions containing a combination of anti-chondrogenesis agents are disclosed. Methods of reducing scleral chondrogensis, reducing one or more ocular chondrogenic proteins, reducing inflammation induced chondrogensis and treating myopia by administering an effective amount of one or more anti-chondrogensis agents are also provided. The pharmaceutical compositions are useful for treating myopia.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition, comprising:
 two anti-chondrogensis agents.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the anti-chondrogenesis agent is an anti-muscarinic agent. 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein the anti-muscarinic agent is atropine. 
     
     
         4 . The pharmaceutical composition of  claim 2 , wherein the anti-muscarinic agent comprises about 0.001% to about 1% by weight atropine. 
     
     
         5 . The pharmaceutical composition of  claim 2 , wherein the anti-muscarinic agent comprises about 0.005% to about 0.05% by weight atropine. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the anti-chondrogensis agent is a non-steroidal anti-inflammatory drug (NSAID). 
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof. 
     
     
         8 . The pharmaceutical composition of  claim 6 , wherein the NSAID comprises about 0.05% to about 1% by weight Ketorolac. 
     
     
         9 . The pharmaceutical composition of  claim 6 , wherein the NSAID comprises about 0.01% to about 0.2% by weight diclofenac. 
     
     
         10 . A method for treating myopia, comprising administering an effective amount of one or more anti-chondrogenesis agents to a myopia subject. 
     
     
         11 . The method of  claim 10 , wherein the anti-chondrogenesis agent is NSAID. 
     
     
         12 . The method of  claim 11 , wherein the NSAID is selected from Ketorolac, Diclofenac, Indomethacin, Bromfenac, Nepafenac, Flurbiprofen, or combination thereof. 
     
     
         13 . The method of  claim 11 , wherein the NSAID comprises about 0.05% to about 1% by weight Ketorolac. 
     
     
         14 . The method of  claim 11 , wherein the NSAID comprises about 0.01% to about 0.2% by weight diclofenac. 
     
     
         15 . The method of  claim 10 , wherein the anti-chondrogenesis agent is an anti-muscarinic agent. 
     
     
         16 . The method of  claim 15 , wherein the anti-muscarinic agent is atropine. 
     
     
         17 . The method of  claim 15 , wherein the anti-muscarinic agent comprises about 0.001% to about 1% by weight atropine. 
     
     
         18 . The method of  claim 15 , wherein the anti-muscarinic agent comprises about 0.005% to about 0.05% by weight atropine.

Join the waitlist — get patent alerts

Track US2016067238A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.